Use of Immune Modulating Agents to Regulate Hyperinflammation in Severe COVID 19: Assessment of Tocilizumab Use in Combination with Steroids.

Mortality remained significantly lower in Group B (OR: 0.06, P < 0.001) and higher in Group C (OR: 2.18, P = 0.062), though the latter did not reach statistical significance [ Table 2 , Figure 1 a, b and Supplementary Table 1 ].

also in 111,027 other papers